35 / 36
Conclusions
• Much progress has been made in research for prostate cancer in the past decade
• The survival of patients with metastatic prostate cancer progressing on androgen-deprivation therapy
(castration-resistant prostate cancer) has improved substantially
• Because of this rapid change in the therapeutic landscape, no robust data exist to inform on the
selection of patients for a specific treatment for metastatic castration-resistant prostate cancer or the
best sequence of administration
• Data from continuing clinical and translational research are urgently needed to improve, and, crucially,
to personalise management